[Federal Register Volume 77, Number 219 (Tuesday, November 13, 2012)]
[Notices]
[Page 67677]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-27567]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration; 
Nektar Therapeutics

    By Notice dated July 17, 2012, and published in the Federal 
Register on July 26, 2012, 77 FR 43862, Nektar Therapeutics, 1112 
Church Street, Huntsville, Alabama 35801, made application by letter to 
the Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of Fentanyl (9801), a basic class of controlled substance 
listed in schedule II.
    The company plans to manufacture the listed controlled substance in 
support of product development.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Nektar Therapeutics to manufacture the listed basic class of controlled 
substance is consistent with the public interest at this time. DEA has 
investigated Nektar Therapeutics to ensure that the company's 
registration is consistent with the public interest. The investigation 
has included inspection and testing of the company's physical security 
systems; verification of the company's compliance with state and local 
laws; and review of the company's background and history. Therefore, 
pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, 
the above named company is granted registration as a bulk manufacturer 
of the basic class of controlled substance listed.

    Dated: November 5, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2012-27567 Filed 11-9-12; 8:45 am]
BILLING CODE 4410-09-P